NewzThe food industry is actively capitalizing on the popularity of anti-obesity medications like Ozempic by marketing products as 'GLP-1 friendly'. This trend reflects a corporate strategy to ride the wave of demand created by these pharmaceutical treatments.
However, these marketing labels lack scientific backing, raising concerns about the validity of health claims associated with these specially designated food packaging items.
In-depth summary · AI, neutral